Reducing the Risk of Recurrence In HR+/HER2- Early Breast Cancer Requires Action: MDT Clinical Case Discussions

Join a multidisciplinary panel for a discussion on current evidence for identifying and managing HR+/HER2- early breast cancer.

Credit available for this activity expires: 9/24/2022 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/959685?src=mkm_podcast_addon_959685